By Carolyn Muyskens ( May 5, 2026, 6:00 PM EDT) -- Amylyx Pharmaceuticals and a class of shareholders are seeking judicial approval for a $6.5 million settlement to resolve allegations that the drugmaker overstated the commercial potential of a treatment for amyotrophic lateral sclerosis, or ALS, that was ultimately shelved....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.